PCSK9 Inhibitor Usage on Target Vessel Dysfunction in patients with hypercholesterolemia after coronary stenting, a Multicenter Randomized Controlled Trial

Not Applicable

• Conditions: Hypercholesterolemia after coronary stenting; hypercholesterolemia

• Registration Number: JPRN-jRCTs071200032
• Lead Sponsor: Matoba Tetsuya

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-09-29
• Last Update Posted: 1 April 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Coronary artery disease patients who underwent successful coronary stenting and will receive investigating lipid-lowering therapy within 8 weeks.
Patients whose LDL-C goal is <70mg/dL according to the Japanese Atherosclerosis Sciety Guideline 2022.
Patients who have LDL-C Cholesterol equal or more than 70 mg/dL and less than 140mg/dL (Friedewad's formula) under the treatment with high-dose or maximum tolerated dose of statins) with or without ezetimibe.

Exclusion Criteria

Patients who are planned coronary revascularization procedure(s) for residual coronary artery lesion(s).
Patients who have undergone a coronary artery bypass grafting.
Patients who have severe left ventricular dysfunction (LVEF<30% by ultrasound).

Study & Design

• Study Type: Interventional
• Study Design: Not specified